The FDA on December 19, 2018 granted accelerated approval to KEYTRUDA® for adult and pediatric patients with recurrent locally advanced or metastatic Merkel Cell Carcinoma (MCC). KEYTRUDA® is a product of Merck & Co. Inc.
Bottom Ad
Advertisement
Subscribe
